NL-OMON27669已完成不适用
A phase II study in mCRPC on the pharmacodynamic effects of budesonide on cabazitaxel (Jevtana®): A randomised, open-label multicenter study: CABARESC.
Dept. of Medical OncologyErasmus MC Rotterdam – Daniel den Hoed Cancer CenterGroene Hilledijk 3013075 EA RotterdamThe Netherlands0 个研究点目标入组 250 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 250
研究概览
简要总结
ieuweboer et al. Effects of budesonide on cabazitaxel pharmacokinetics and cabazitaxel-induced diarrhea: A randomized open-label multicenter phase II study. Clin Cancer Res. 2016 Oct 4 [Epub ahead of print]
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Metastatic castrate resistant prostate cancer (mCRPC) patients with documented disease progression;
- •2. If measureable disease: documented disease progression as defined in RECIST criteria v 1.1;
排除标准
- •1. Impossibility or unwillingness to take oral drugs;
- •2. Serious illness or medical unstable condition requiring treatment, symptomatic CNS-metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent;
研究者
相似试验
已完成
不适用
Studying the influence of budesonide on the exposure of cabazitaxel (Jevtana®) in patients with prostate cancer.prostate cancercabazitaxelbudesonideNL-OMON21762Erasmus Medical Center, Daniel den Hoed Cancer Center18
终止
2 期
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With DocetaxelDiarrheaHormone-resistant Prostate CancerRecurrent Prostate CancerStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Prostate CancerNCT01469338University of Southern California9
已完成
1 期
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate CancerProstate CancerNCT01511536Sanofi38
进行中（未招募）
1 期
Cabazitaxel chemotherapy for advanced and/or metastatic cancer of the penis.EUCTR2014-002336-14-GBniversity Hosptial Bristol NHS Foundation trust9
进行中（未招募）
不适用
A study to evaluate the effectiveness of combination cabazitaxel and cisplatin chemotherapy before surgery for invasive bladder cancerEUCTR2011-004090-82-GBniversity Hospitals Bristol NHS Foundation Trust Research and Innovation Department30